Identification of new markers and drug target candidates for triple negative brea

描述(由申请人提供)： 三阴性乳腺癌是一种特别恶性且难以治疗的疾病。目前，还没有确定的生物标志物和药物靶点来帮助诊断和预后三阴性乳腺癌，并为基于理论基础的药物发现和治疗方案提供信息。该项目将利用最近发展的大规模后基因组方法来分析三阴性乳腺肿瘤的蛋白质组，并建立转移性和非转移性肿瘤的定量蛋白质表达谱。该项目的主要目标是识别和验证在转移性三阴性乳腺癌中特异过度表达的蛋白质。10个转移性和10个非转移性三阴性乳腺肿瘤将在2000多种蛋白质的分析深度下进行分析。通过这一大规模图谱确定的差异表达蛋白质将通过免疫化学方法和靶向质谱分析进行验证。获得的数据将提供候选蛋白质标记物和潜在的药物靶点，可用于开发新的、更个性化和更有效的三阴性乳腺癌治疗方法。

DESCRIPTION (provided by applicant): Triple negative breast cancer is a particularly malignant and hard to treat type of the disease. At the present there are no established biomarkers and drug targets to aid the diagnosis and prognosis of triple negative breast cancer and to inform rationale- based drug discovery and treatment options. This project will utilize recently developed large-scale post-genomic methods to analyze the proteomes of triple negative breast tumors and establish quantitative protein expression profiles of node- metastatic and non-metastatic tumors. The main objective of the project is to identify and validate proteins which are specifically over expressed in metastatic triple negative breast cancer. Ten metastatic and ten non-metastatic triple negative breast tumors will be profiled at an analytical depth of more than 2,000 proteins. The differentially expressed proteins identified by this large-scale profiling will be validated by immunochemical methods and targeted mass spectrometry assays. The obtained data will provide candidate protein markers and potential drug targets that can be used to develop new, more individualized and more efficient therapies for triple negative breast cancer.